Enzene Biosciences has recently announced to open its first manufacturing site in the United States. The location settled in Hopewell near Princeton, New Jersey, is set to become an important hub in the global biotech industry. The facility, aimed for completion in June 2024, has already received considerable interest from clients to support Enzene’s patented continuous manufacturing technology.
Enzene Biosciences, the Continuous Bioprocess Manufacturing specialist, is driven by a team of dedicated scientists united by a shared mission to make a positive impact on human lives. Their goal is to emerge as one of the global player in the biotech industry. Enzene focuses on embracing innovation as a core aspect of their identity. With technologies that shape the future, they have made investments enabling the advanced development of products “From cell to vial”.
Situated within the Princeton West Innovation Campus, Enzene’s new plant holds a prime position at the heart of the US. Northeast Corridor, offering convenient access for collaborations with established biotech and pharmaceutical firms worldwide.
Himanshu Gadgil, CEO of Enzene Biosciences, highlighted the reason behind this remarkable move, stating, “Recognizing the challenges faced by small biotech firms and startups in securing clinical phase capacity, Enzene Inc has been established in the US. Our fundamental mission is to create access equity across the global healthcare ecosystem.”
The United States, being the birthplace of numerous molecules forming the backbone of life-saving drugs, often witnesses a struggle for clinical phase capacity among smaller players. Enzene’s decision to set up a manufacturing base in the U.S reflects its commitment to addressing this gap and supporting emerging innovative biotech firms.
Mr Gadgil emphasized, “We remain confident that our patented EnzeneX technology platform and proven track record in achieving cost-effective biologics manufacturing will position us as a partner of choice for biotech companies striving to bring promising molecules to market.”
The 54,000 square feet manufacturing plant is set to distinguish itself as one of the few biologics-focused continuous manufacturing bases established by an Indian firm in the New Jersey, with its rich tradition of supporting pharmaceutical manufacturing excellence, emerged as the ideal choice for Enzene Biosciences. The region also has a pool of highly skilled talent, supporting the company’s confidence in securing skilled labour for sustained manufacturing operations.
Sandeep Singh, Managing Director of Alkem Industries, stressed Enzene’s dedication to delivering trusted and affordable solutions in the global healthcare ecosystem, stating, “Enzene Biosciences’ strategic expansion into the U.S. CDMO space aligns with our vision. With successful CDMO operations in India supporting global pharmaceutical firms, establishing a GMP-compliant continuous manufacturing base in the US was a logical progression.
Mr Singh further explained, “The focus now is on enhancing Enzene’s manufacturing capacities at the Hopewell plant to provide cost-effective, quality local manufacturing for early-stage biological assets.”
Having recently inaugurated a facility in Pune, Enzene Biosciences is completely prepared for growth, focusing on expanding discovery-focused capabilities, increasing manufacturing capacities, and securing USDA and USFDA approval for the US facility within the next year. The company’s plans extend beyond borders, with plans to gradually expand operations across the five major markets for biologics and biosimilars—EU, USA, Canada, Australia, and Japan.
